GMAB vs UTHR
Genmab A/S vs United Therapeutics — AI-powered side-by-side comparison
VS
UTHR
United Therapeutics
72
Buy
| Metric | GMAB | UTHR |
|---|
| AI Score |
60
|
72
|
| Price |
$30.82
|
$514.89
|
| P/E Ratio |
24.04×
|
17.05×
|
| ROE |
16.5%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
39.9%
|
86.1%
|
| Debt / Equity |
0.89×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
72.5
|
52.2
|
| Beta |
0.685
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for GMAB versus UTHR.
UTHR leads by 12 points.
UTHR scores 72/100 (Buy) versus GMAB at 60/100 (Buy).
GMAB Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- EPS declining -25.3% YoY despite any revenue growth — Growth
- RSI at 73 is in overbought territory — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.